Search the Newsreel

Tekcapital plc Reports Earnings Results for the Half Year Ended June 30, 2026

Analysts Offer Insights on Industrial Goods Companies: Ametek (AME) and Rockwell Automation (ROK)

KeyBanc analysts Steve Barger and Kenneth Newman reiterated Buy ratings for Ametek (AME) and Rockwell Automation (ROK), respectively, in the Industrial Goods sector. Barger set a $295.00 price target for Ametek, while Newman assigned a $510.00 price target for Rockwell Automation. Both companies currently …

AMETEK (AME) Is Up 8.3% After Record Q2 Results And Raised 2026 Guidance - What's Changed

AMETEK (AME) reported record Q2 2026 results with increased sales and net income, leading to an 8.3% stock increase. The company raised its full-year 2026 guidance, projecting 10% sales growth and higher GAAP diluted EPS, supported by strong order intake and acquisitions. This update …

Alpha Teknova (NASDAQ: TKNO) lifts Q2 revenue to $12,185 thousand

NewtekOne (NEWT) Earnings Date and Reports 2026

Mitek Systems (MITK) Earnings Date and Reports 2026

Mitek Systems (MITK) Q3 Earnings and Revenues Beat Estimates

Precision Trading with Camtek Ltd. (CAMT) Risk Zones

This article provides an AI-generated analysis for Camtek Ltd. (CAMT), highlighting current market sentiment, risk zones, and various trading strategies. It outlines distinct entry and exit points, target prices, and stop losses for position trading, momentum breakout, and risk hedging, based on near-term, mid-term, …

Alpha Teknova (Nasdaq: TKNO) raises 2026 guidance after Q2 growth

Alpha Teknova (Nasdaq: TKNO) reported strong Q2 2026 financial results, with revenue increasing 18% to $12.2 million and improved profitability metrics. Following this performance, the company raised its 2026 revenue guidance to $45-$47 million and lowered its Free Cash Outflow expectations to less than …

Flotek Industries, Inc. Stock 12‑Month Price Target Raised to $29.58, Implies 5% Upside

The 12-month average price target for Flotek Industries, Inc. (FTK) stock has increased from $26.72 to $29.58, according to 7 analysts. This new target suggests a potential upside of approximately 5% from its August 4th closing price. The consensus analyst rating remains a "Buy," …

Flotek Industries (FTK) Stock Jumps As Data Analytics Becomes Profit Engine

Cytek Biosciences (NASDAQ:CTKB) Posts Earnings Results, Hits Estimates

Cytek Biosciences Reports Second Quarter 2026 Financial Results

Cytek Biosciences reported its second-quarter 2026 financial results, with total revenue reaching $48.1 million, a 6% increase year-over-year. The company also announced the launch of new instruments, the Cytek Borealis™ and updated Cytek Aurora™ Evo configurations, and updated its full-year 2026 revenue guidance to …

Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ...

Cytek Biosciences (CTKB) reported a 6% year-over-year revenue increase to $48.1 million in Q2 2026, driven by strong growth in the US and China, particularly from high-end instrument sales and services. Despite this, the company saw a widened GAAP net loss of $12.2 million …

Teknova targets less than $8M 2026 free cash outflow as it lifts revenue guide to $45M-$47M

Earnings Call Insights: Alpha Teknova (TKNO) Q2 2026 MANAGEMENT VIEW * Stephen Gunstream (President, CEO & Director) said, “Revenue grew 18% compared to the second quarter 2025, exceeding $12 million for the quarter, the highest quarterly revenue in Teknova's 30-year history,” and tied the …

AMETEK (NYSE:AME) Price Target Raised to $285.00 at DA Davidson

DA Davidson has increased its price target for AMETEK (NYSE:AME) to $285.00 from $265.00, maintaining a "buy" rating on the stock, implying an 11.9% upside. This follows AMETEK's strong Q2 2026 earnings report, where the company beat analyst estimates with $2.09 EPS and $2.04 …

Earnings call transcript: Teknova posts record Q2 2026 revenue and raises outlook

Teknova (TKNO) reported record Q2 2026 revenue of $12.2 million and a narrower-than-expected loss of $0.06 per share, leading the company to raise its full-year 2026 revenue guidance to $45-$47 million. Despite the strong financial performance and the launch of an AI-powered custom order …

Cytek Biosciences Q2 GAAP net loss widens to $12.2 million; revenue rises 6% year over year to $48.1 million

Cytek Biosciences reported its Q2 2026 financial results, showing a 6% year-over-year increase in revenue to $48.1 million. Despite the revenue growth, the company's GAAP net loss widened to $12.2 million, and its GAAP operating loss increased to $11.4 million. The gross margin improved …

Camtek (CAMT) Dips More Than Broader Market: What You Should Know

Camtek (CAMT) closed at $147.60 in the latest trading session, marking a -2.65% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.17%. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq depreciated by …

Teknova Reports Second Quarter 2026 Financial Results

Teknova (Nasdaq: TKNO) announced strong financial results for the second quarter of 2026, with total revenue reaching $12.2 million, an 18% increase year-over-year. The company also raised its full-year 2026 revenue guidance to $45-$47 million and introduced its AI-powered Build-Tek™ custom order configurator to …

Teknova Q2 2026 Earnings: Revenue Growth Drives Higher Guidance

Teknova (Nasdaq: TKNO) reported a strong Q2 2026 with revenue up 18% to $12.2 million, narrowing its GAAP diluted EPS loss to $0.06. The company saw broad-based growth across its Lab Essentials and Clinical Solutions segments, leading to improved operating leverage and significantly reduced …

Cytek Biosciences (CTKB) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss

Cytek Biosciences (CTKB) reported Q2 2026 revenue of $48.1 million, a 5.6% increase year-over-year, and gross profit rose by 18.7% to $28.3 million. Despite revenue growth, the company posted a net loss of $12.2 million, or $(0.09) diluted EPS, missing analyst expectations of $(0.0867) …

Cytek Q2 2026 Earnings: Revenue Rose 6% as Losses Widened

Cytek (Nasdaq: CTKB) reported a 6% increase in Q2 2026 revenue to $48.1 million, driven by instrument growth in the U.S. and China and higher service revenue. However, the company's net losses widened significantly due to a faster increase in operating expenses and weaker …

Cytek Biosciences GAAP EPS of -$0.09 in-line, revenue of $48.1M misses by $0.51M

* Cytek Biosciences press release [https://seekingalpha.com/pr/20608750-cytek-biosciences-reports-second-quarter-2026-financial-results] (CTKB [https://seekingalpha.com/symbol/CTKB]): Q2 GAAP EPS of -$0.09 in-line. * Revenue of $48.1M (+5.5% Y/Y) misses by $0.51M. * GAAP gross profit was $28.3 million for the second quarter of 2026, a 19% increase compared to the second quarter …

Earnings call transcript: Cytek Biosciences posts q2 2026 revenue growth, shares fall

Cytek Biosciences reported a 6% increase in second-quarter 2026 revenue to $48.1 million, driven by strong demand in the U.S. and China, but also announced a wider net loss and negative adjusted EBITDA. Despite raising the low end of its full-year revenue guidance, shares …

Mustek predicts slide in profit after renewable energy boom in South Africa ends

Cytek Biosciences Q2 Earnings: Revenue Up 6% to $48.1M | CTKB Stock News

Cytek Biosciences reported a 6% year-over-year revenue increase to $48.1 million in Q2 2026, driven by strong instrument sales in the U.S. and China and higher service revenue. Despite the revenue growth and improved gross margins, the company's net loss widened to $12.2 million, …

AMETEK (NYSE:AME) Price Target Raised to $280.00 at BNP Paribas Exane

BNP Paribas Exane raised AMETEK's price target to $280 from $270, maintaining an "outperform" rating with a potential upside of 9.58%. This follows AMETEK's strong Q2 2026 results, surpassing analyst expectations with EPS of $2.09 and revenue of $2.04 billion, driven by robust performance …

AME Stock Price and Chart — NYSE:AME

This article provides a comprehensive overview of AMETEK, Inc. (AME) stock, including its current price, historical performance, key financial metrics, and latest earnings report. It also features analyst ratings, investment ideas from the TradingView community, and a list of ETFs holding the stock, alongside …

Citigroup Adjusts Price Target on AMETEK to $261 From $257

Citigroup has adjusted its price target for AMETEK (AME) shares to $261, up from the previous $257. This change was published on August 5, 2026, at 11:28 am EDT. The article also lists several other analyst target price adjustments for AMETEK from various financial …

Flotek Industries (NYSE:FTK) Shares Up 29.7% on Better-Than-Expected Earnings

Flotek Industries (NYSE:FTK) saw its shares jump 29.7% after reporting significantly better-than-expected earnings and revenue. The oil and gas company posted an EPS of $0.26 against an estimated $0.13, and revenue of $99.37 million, far exceeding the $69.51 million forecast. Analyst sentiment remains positive, …

AMETEK Q2 Earnings Surpass Expectations, Revenues Rise Y/Y

AMETEK (AME) reported strong second-quarter 2026 results, with both earnings and revenues surpassing Zacks Consensus Estimates. The company saw a 17% increase in non-GAAP earnings per share year-over-year and a 15% rise in top-line revenues, driven by growth in its EIG and EMG segments. …

RBC raises Ametek stock price target on strong Q2 results

RBC Capital has raised its price target for Ametek Inc. (NYSE:AME) to $291 from $260, maintaining an Outperform rating, following the company's strong second-quarter 2026 results. Ametek reported significant orders growth of 28% and organic sales growth of 10%, driven by strength in aerospace, …

Teknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in Minutes

Teknova has launched Build-Tek™, an AI-powered custom order configurator for complex reagent requests, expanding on its 2024 buffer configurator. This tool allows therapeutic and diagnostic developers to design custom products and submit quote requests in minutes, significantly reducing the time from weeks to days. …

Teknova AI lets developers configure custom reagents in minutes

Teknova (Nasdaq: TKNO) has launched Build-Tek™, an AI-powered configurator that allows therapeutic and diagnostic developers to design complex custom reagents and submit quote requests in minutes. This system guides users through various specifications, significantly reducing the time for quote generation from weeks to two …

Reeder Teknoloji Sanayi ve Ticaret A.S. İşlem Fikirleri — BIST:REEDR